Influenza A virus
Influenza A virus (IAV) is an enveloped, negative-sense RNA virus in the family Orthomyxoviridae and is a major cause of seasonal influenza in humans and many animal species.
Influenza A virus (IAV) is an enveloped, negative-sense RNA virus in the family Orthomyxoviridae and is a major cause of seasonal influenza in humans and many animal species. It is biologically important because of its high mutation rate, antigenic variation, and capacity for reassortment, all of which contribute to recurrent epidemics, antiviral resistance, and occasional pandemics. The virus primarily infects the respiratory epithelium, which serves as the first immunological barrier and a key site of early host defense.
IAV is medically significant because it can cause illness ranging from uncomplicated upper respiratory infection to severe viral pneumonia, acute lung injury, and death, particularly in young children, older adults, pregnant individuals, and immunocompromised patients. Host responses involving pathways such as MAVS signaling, STAT1-associated inflammation, Toll-like receptor 7/8 signaling, and the toll like receptor 4 (TLR4)/P2X7-NLRP3 axis have been studied in relation to disease severity and antiviral defense. Influenza A virus is also a major target for vaccination and antiviral drug development because of its broad public health burden and its ability to evade immunity through antigenic drift and subtype diversity.
Where the papers sit
16 papers from the last 6 months study Influenza A virus directly · updated from PubMed 12 Oct 2026
Study type 0 clinical trials · 6 observational · 3 human data · 6 preclinical · 1 unclassified
Themes one subject · 1 new direction
Those 16 are all about one subject.
-
Influenza a Biology and Control
Work spans rapid CRISPR diagnostics, vaccine design, antiviral discovery, viral surveillance, and clinical severity assessment. Vaccine studies pursue mucosal, broadly protective, and adjuvant-free responses, while diagnostic studies target multiplex, one-pot detection. Other papers address vaccination gaps, circulating strains, liver injury, and mortality without a shared mechanistic or clinical endpoint. The cluster therefore supports no single field-wide direction beyond broad influenza prevention and management.
Hematopoietic stem-cell gene editing recasts influenza A virus prevention as an endogenous antibody-production strategy
The hematopoietic stem cell gene-editing study uses influenza A virus as the challenge target for an engineered B-lymphocyte protein-factory platform, rather than as an infection addressed by a conventional vaccine, diagnostic, or directly administered antiviral. In mice, transplanted edited hematopoietic stem and progenitor cells generated antigen-responsive plasma cells that produced an anti-influenza broadly neutralizing antibody and provided universal protection against heterologous lethal challenge. This makes long-term, self-amplifying production of protective antibody by engineered host cells a distinct preventive role for influenza A virus within the set 41990179Apr.
Papers
The 16 papers from the last 6 months that study Influenza A virus directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Influenza a Biology and Control (16)
- Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics. Proceedings of the National Academy of Sciences of the United States of America · 9 Sept 2026 PMID 42715083
- Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus. Vaccine · 11 Jul 2026 PMID 42435621
- Discovery of broad-spectrum antiviral activity in Amaryllidaceae alkaloids. Biochemical and biophysical research communications · 8 Jul 2026 PMID 42419220
- Exploring molecular characterization circulating influenza A and B viruses in Tehran, Iran. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 1 Jul 2026 PMID 42384313
- Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies. Human vaccines & immunotherapeutics · 29 Jun 2026 PMID 42373575
- Spatial Tail Design in Ionizable Lipids Enhances the Safety and Efficacy of mRNA Delivery. Small methods · 26 Jun 2026 PMID 42359610
- Hypertransaminasemia Is a Marker of Severity in Children Hospitalized for Influenza. Influenza and other respiratory viruses · 24 Jun 2026 PMID 42340130
- Concordance Between Maternal and Infant COVID-19 and Influenza Vaccination Status. Pediatrics · 23 Jun 2026 PMID 42336370
- Association between COVID-19 booster vaccination and influenza mortality: a nationwide retrospective cohort study using the SIVEP-Gripe database in Brazil. Immunologic research · 21 Jun 2026 PMID 42324378
- A rapid, multiplex, one-pot CRISPR/Dx system for visual detection of influenza A, influenza B, and respiratory syncytial viruses. Analytical methods : advancing methods and applications · 16 Jun 2026 PMID 42299927
- Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study. Vaccine · 19 May 2026 PMID 42155244
- Harnessing CRISPR-Cas12 and Microfluidics Chips for Multiplex Respiratory Pathogens Diagnosis. ACS sensors · 15 May 2026 PMID 42138264
- Limited 'heft' of weight-based outcomes in predicting influenza A virus disease severity in ferrets. PLoS computational biology · 8 May 2026 PMID 42102174
- An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America · 29 Apr 2026 PMID 42054358
- A dual-adjuvanted HA stem nanoparticle vaccine elicits a multifunctional antibody response that is associated with protection in newborn monkeys. Cell reports. Medicine · 17 Apr 2026 PMID 41997140
- B lymphocyte protein factories produced by hematopoietic stem cell gene editing. Science (New York, N.Y.) · 16 Apr 2026 PMID 41990179
By study type
Observational studies and case reports (6)
- Exploring molecular characterization circulating influenza A and B viruses in Tehran, Iran. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 1 Jul 2026 PMID 42384313
- Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies. Human vaccines & immunotherapeutics · 29 Jun 2026 PMID 42373575
- Hypertransaminasemia Is a Marker of Severity in Children Hospitalized for Influenza. Influenza and other respiratory viruses · 24 Jun 2026 PMID 42340130
- Concordance Between Maternal and Infant COVID-19 and Influenza Vaccination Status. Pediatrics · 23 Jun 2026 PMID 42336370
- Association between COVID-19 booster vaccination and influenza mortality: a nationwide retrospective cohort study using the SIVEP-Gripe database in Brazil. Immunologic research · 21 Jun 2026 PMID 42324378
- Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study. Vaccine · 19 May 2026 PMID 42155244
Human data, design not indexed (3)
- Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics. Proceedings of the National Academy of Sciences of the United States of America · 9 Sept 2026 PMID 42715083
- A rapid, multiplex, one-pot CRISPR/Dx system for visual detection of influenza A, influenza B, and respiratory syncytial viruses. Analytical methods : advancing methods and applications · 16 Jun 2026 PMID 42299927
- Harnessing CRISPR-Cas12 and Microfluidics Chips for Multiplex Respiratory Pathogens Diagnosis. ACS sensors · 15 May 2026 PMID 42138264
Preclinical: animal, cell and lab studies (6)
- Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus. Vaccine · 11 Jul 2026 PMID 42435621
- Discovery of broad-spectrum antiviral activity in Amaryllidaceae alkaloids. Biochemical and biophysical research communications · 8 Jul 2026 PMID 42419220
- Limited 'heft' of weight-based outcomes in predicting influenza A virus disease severity in ferrets. PLoS computational biology · 8 May 2026 PMID 42102174
- An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America · 29 Apr 2026 PMID 42054358
- A dual-adjuvanted HA stem nanoparticle vaccine elicits a multifunctional antibody response that is associated with protection in newborn monkeys. Cell reports. Medicine · 17 Apr 2026 PMID 41997140
- B lymphocyte protein factories produced by hematopoietic stem cell gene editing. Science (New York, N.Y.) · 16 Apr 2026 PMID 41990179
Unclassified: not yet indexed with MeSH (1)
- Spatial Tail Design in Ionizable Lipids Enhances the Safety and Efficacy of mRNA Delivery. Small methods · 26 Jun 2026 PMID 42359610
Written from 16 PubMed abstracts, each one listed by PMID above. Published: 2026-06-21. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.